SORTIS Invest is pleased to announce its role as the exclusive financial advisor to the shareholders of Medical Center Hera EOOD and Medical Center Hera – Kyustendil EOOD (together “Hera Clinics” or “Hera”) in the sale of the companies to FutureMeds, a European network of dedicated clinical research sites backed by Phoenix Equity Partners. The transaction was completed on 19 October 2026, following receipt of the required regulatory approvals. Financial terms were not disclosed.
Hera Clinics, headquartered in Sofia with further centres in Montana and Kyustendil, was founded in 2019 by clinical research professionals with more than fifteen years of experience in clinical trials and site management. The company combines a multidisciplinary outpatient practice of more than 70 medical specialists – covering cardiology, respiratory medicine, endocrinology, gastroenterology, neurology, dermatology, rheumatology and internal medicine – with a purpose-built clinical research facility, including an IMP pharmacy with controlled access, an in-house laboratory and imaging and endoscopy capabilities. Since 2019 Hera has supported more than 100,000 patients and has taken part in more than 200 clinical trials for global pharmaceutical sponsors and CROs, achieving global top-recruiter status in more than ten studies. Since 2023 Hera has been the first Bulgarian Prime Site of IQVIA, and in 2025 it joined the PPD Select site partnership programme.

With the acquisition of Hera, FutureMeds builds a more connected clinical research platform across Bulgaria, extending patient access to trials and new treatments in four cities – Sofia, Plovdiv, Montana and Kyustendil. Hera contributes its long-standing patient relationships, the breadth of its medical specialties and its depth in central nervous system and other strategic therapeutic areas; FutureMeds adds its dedicated research-site model, its European network and its expertise across multiple therapeutic areas such as oncology. According to FutureMeds, FutureMeds Bulgaria will thereby become one of the key players on the Bulgarian market.
Hera will continue to operate under its established name, with its current leadership and operating model, and its doctors will continue to make all decisions on patient care. Mr. Emil Kostov remains at the helm of the business. FutureMeds will initially support Hera in IT, feasibility and central operations, so that Hera’s medical and research teams can concentrate on patients and active programmes. Hera will also gain access to selected FutureMeds digital systems and tools designed to reduce administrative burden. For Hera’s teams, the combination opens access to wider expertise, operational support and a larger number of international clinical research opportunities, and creates the opportunity to grow the business internationally and participate in larger multinational programmes.
The transaction is one of the most significant private-sector M&A deals in the Bulgarian clinical research sector in recent years. It reflects the growing strategic interest of international, private-equity-backed site networks in Central and Eastern Europe, where high-quality investigator sites, fast patient recruitment and access to large and diverse patient populations are increasingly sought after by global sponsors and CROs.
Commenting on the transaction, Mr. Emil Kostov, MScPharm, PhD, Founder and Director of Medical Center Hera, said: “Hera’s team is excited about FutureMeds’ acquisition of Hera and looks forward to contributing to its mission of expanding access to clinical research. We share a patient-focused culture and a practical approach to study delivery. The acquisition allows us to connect our local expertise and relationships with a wider European network while keeping our focus on the patients and programmes we support. SORTIS Invest provided invaluable help to us through all the phases of the process and in negotiating a complex cross-border transaction. They also helped us develop financial reporting and forecasting tools that we started using in our daily operations and in our budgeting process. SORTIS were impeccable in protecting the interests of the selling shareholders.”
Dr. Radoslaw Janiak, CEO of FutureMeds, said: “Our Bulgarian team have built a strong reputation, showing what can be achieved when a dedicated site model is combined with close collaboration across local healthcare. The acquisition of Medical Center Hera allows us to build on that approach. By bringing Hera’s medical community together with our clinical research infrastructure, we can create a stronger and more predictable platform for sponsors and CROs operating in Bulgaria. FutureMeds Bulgaria will become one of the key players on the market allowing patients to benefit from participation in a variety of clinical trials.”
Mr. Martin Paev, CFA, the Executive Director of SORTIS Invest, stated: “We are proud to have supported Hera Clinics in this transaction. In just seven years, Mr. Kostov and his partners have built the leading clinical research site management organisation in Bulgaria, with recruitment performance and quality metrics that compete on a global level. We see a great cultural fit with FutureMeds: the two organisations share a patient-focused culture and are highly complementary in geographies, therapeutic areas and operating models. We believe this transaction will create significant value for all parties, and we are pleased to have secured a structure that rewards what Hera’s founders have built while keeping them at the helm of the company.”
ABOUT HERA CLINICS
Medical Center Hera (Hera Clinics) is a Bulgarian network of clinical research sites and multidisciplinary outpatient clinics in Sofia, Montana and Kyustendil. Founded in 2019 by clinical research professionals, Hera combines more than 70 medical specialists with a dedicated clinical research infrastructure and has enrolled patients in more than 200 clinical trials across a broad range of therapeutic areas for global pharmaceutical sponsors and CROs. Hera is IQVIA’s first Bulgarian Prime Site and a member of the PPD Select site partnership programme.
ABOUT FUTUREMEDS
FutureMeds is a European clinical research organisation operating a network of dedicated clinical research sites across seven European countries, including sites in Sofia and Plovdiv in Bulgaria. Its teams work with doctors, patients, pharmaceutical companies and research organisations to deliver clinical trials at its sites and, through FutureMeds @home, in patients’ homes, and have supported more than 32,000 clinical trial participants across Europe. FutureMeds is backed by the UK private equity firm Phoenix Equity Partners.
ABOUT SORTIS INVEST
SORTIS Invest is a prominent investment banking boutique, based in Sofia, Bulgaria, part of SORTIS Group. It is a member of Globalscope Partners, a global family of 55 independent M&A firms across six continents with a team of 600+ professionals, which completed 206 mergers and acquisitions and private equity deals worldwide with a total enterprise value of USD 33.4 bln in 2025.
SORTIS Invest has advised clients in various sectors including Telecommunications, Media and Technology (TMT), financial services, food and beverages, life sciences, chemicals, education, defense, manufacturing, commerce, energy, mining, transport and logistics, hospitality and real estate.
